Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated SARS-CoV-2 Spike RBD Protein (R346S, N394S, Y449N, E484K, F490S, N501Y), His,Avitag™, 25µg  

Recombinant Biotinylated SARS-CoV-2 Spike RBD Protein (R346S, N394S, Y449N, E484K, F490S, N501Y), His,Avitag™, 25µg

Recombinant Biotinylated SARS-CoV-2 Spike RBD Protein (R346S, N394S, Y449N, E484K, F490S, N501Y), AA Arg 319 - Lys 537, expressed from human 293 cells (HEK293), His, Avitag

Synonyms: Recombinant, Spike, S protein RBD, Spike glycoprotein Receptor-binding domain, S glycoprotein RBD, Spike protein RBD, COVID-19

More details

SPD-C82Er-25

Availability: within 7 days

494,00 €

Background
It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant Biotinylated SARS-CoV-2 Spike RBD (R346S, N394S, Y449N, E484K, F490S, N501Y), His,Avitag (SPD-C82Er) is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Lys 537 (Accession # QHD43416.1(R346S, N394S, Y449N, E484K, F490S, N501Y)). The mutations (R346S, N394S, Y449N, E484K, F490S, N501Y) were identified in the SARS-CoV-2 variant (PANGO Lineage: B.1.640.2).
N-terminus: Arg 319

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 28.1 kDa. The protein migrates as 33-38 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2
Maeda, Toyoda, Kuwata et al
Int J Mol Sci (2024) 25 (2)
(2) "Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine
Muranishi, Kinoshita, Inoue et al
Vaccines (Basel) (2023) 12 (1)
(3) "Long-Term SARS-CoV-2-Specific Humoral and T Cell Responses after the BNT162b2 or BBIBP-CorV Booster and the Incidence of Breakthrough Infections among Healthcare Workers"
Matula, Bekő, Király et al
Vaccines (Basel) (2023) 12 (1)
Showing 1-3 of 4353 papers.